News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
381,043 Results
Type
Article (15139)
Company Profile (127)
Press Release (365777)
Section
Business (117811)
Career Advice (544)
Deals (20169)
Drug Delivery (29)
Drug Development (33981)
Employer Resources (53)
FDA (9218)
Job Trends (8084)
News (183009)
Policy (13249)
Tag
Academia (1373)
Alliances (35674)
Alzheimer's disease (503)
Approvals (9205)
Artificial intelligence (160)
Bankruptcy (139)
Best Places to Work (6854)
Biotechnology (96)
Breast cancer (91)
Cancer (758)
Career advice (468)
CAR-T (74)
Cell therapy (207)
Clinical research (26565)
Collaboration (419)
Compensation (92)
COVID-19 (1173)
C-suite (81)
Data (751)
Diabetes (65)
Diagnostics (4942)
Earnings (40833)
Events (53961)
Executive appointments (262)
FDA (9625)
Funding (337)
Gene editing (60)
Gene therapy (127)
GLP-1 (209)
Government (1315)
Healthcare (10431)
Infectious disease (1228)
IPO (8891)
Job creations (1503)
Job search strategy (414)
Layoffs (118)
Legal (2703)
Lung cancer (91)
Manufacturing (134)
Medical device (11507)
Medtech (11512)
Mergers & acquisitions (11484)
Metabolic disorders (158)
Neuroscience (650)
NextGen: Class of 2025 (3721)
Non-profit (1671)
Northern California (907)
Obesity (76)
Opinion (75)
Patents (82)
People (33481)
Phase I (9520)
Phase II (11961)
Phase III (7933)
Pipeline (302)
Postmarket research (595)
Preclinical (4252)
Press Release (66)
Radiopharmaceuticals (157)
Rare diseases (121)
Real estate (3457)
Regulatory (9830)
Research institute (1331)
Resumes & cover letters (98)
Series A (64)
Southern California (916)
Startups (2562)
United States (8906)
Vaccines (255)
Date
Today (117)
Last 7 days (528)
Last 30 days (1224)
Last 365 days (19760)
2025 (745)
2024 (19911)
2023 (23440)
2022 (32252)
2021 (34143)
2020 (32221)
2019 (27223)
2018 (20510)
2017 (19714)
2016 (18470)
2015 (21665)
2014 (15981)
2013 (13377)
2012 (14524)
2011 (14961)
2010 (13644)
Location
Africa (331)
Arizona (105)
Asia (24433)
Australia (4245)
California (2221)
Canada (920)
China (184)
Colorado (129)
Connecticut (106)
Europe (50436)
Florida (347)
Georgia (99)
Illinois (230)
Indiana (127)
Japan (70)
Kansas (78)
Maryland (371)
Massachusetts (1586)
Michigan (158)
Minnesota (212)
New Jersey (660)
New York (605)
North Carolina (438)
Northern California (907)
Ohio (84)
Pennsylvania (439)
South America (526)
Southern California (916)
Texas (350)
Utah (78)
Washington State (269)
381,043 Results for "hutchinson technology incorporated".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).
January 18, 2024
·
6 min read
Deals
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
Sentynl Therapeutics, Inc. (Sentynl) and Eiger BioPharmaceuticals, Inc. (OTC: EIGRQ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced the closing of the sale of Eiger’s Zokinvy® (lonafarnib) program to Sentynl.
May 3, 2024
·
11 min read
Press Releases
Axxam S.p.A. accelerates global expansion incorporating Axxam Inc.
December 13, 2024
·
2 min read
Press Releases
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash
January 6, 2025
·
9 min read
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe
Arecor Therapeutics plc, the biopharmaceutical company advancing ’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a product, AT220, incorporating its proprietary Arestat™ technology platform.
November 17, 2023
·
2 min read
Press Releases
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
November 6, 2024
·
8 min read
BioMidwest
Prime/MRx’s new Pharmacy Match technology-driven solution expands specialty pharmacy access and choice
Prime Therapeutics LLC and Magellan Rx Management launched Pharmacy Match, a technology-enabled specialty pharmacy solution designed to drive competition through an expanded specialty pharmacy network and to lower drug costs for plan sponsors.
June 19, 2024
·
4 min read
Press Releases
Biocoat Incorporated Secures New Patent for Non-PFAS Inner Diameter Coating
August 28, 2024
·
2 min read
Press Releases
Medeologix Expands Hydrophilic Coating Services, Partners with Biocoat® Incorporated to Solidify Position as The Bay Area’s Premier Catheter Solutions Provider
November 6, 2024
·
3 min read
Artificial intelligence
FDA’s New AI Guidance Highlights Risks of Technology, Urges Early Sponsor Engagement
The FDA’s guidance on AI in drug development points to potentially life-threatening consequences of the technology, highlighting the importance of providing the regulator with detailed information regarding models’ development and maintenance.
January 7, 2025
·
2 min read
·
Tristan Manalac
1 of 38,105
Next
